Letters to the Editor

Low Omicron BA.4 and BA.5 neutralising activity and breakthrough COVID-19 following pre-exposure prophylaxis with tixagevimab plus cilgavimab in vaccinated patients with autoimmune disease

C.M. Connolly¹, A.H. Karaba², T. Po-Yu chiang³, M. Teles⁴, J.D. Kim⁵, T. Scott Johnson⁶, J.L. Alejo⁷, D.L. Segev⁸, L. Christopher-Stine⁹, W.A. Werbel¹⁰, J.J. Paik¹¹

Author information

Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Department of Surgery, NYU Grossman School of Medicine, New York, NY, USA.
Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jpaik1@jhmi.edu

CER16443
2023 Vol.41, N°5
PI 1202, PF 1203
Letters to the Editor

Free to view
(click on article PDF icon to read the article)

PMID: 36826787 [PubMed]

Received: 08/12/2022
Accepted : 16/01/2023
In Press: 23/02/2023
Published: 03/05/2023

DOI: https://doi.org/10.55563/clinexprheumatol/pfli7o